Targeting the Microbiota–Gut–Brain Axis: Emerging Nanomedicine Approaches for Neurodegenerative Diseases
European Journal of Neuroscience · 2026-07 · 64 (2)
DOI: 10.1111/ejn.70606 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Journal of Neuroscience, online erschienen am 26.07.2026. Verfasst von Reda M Mansour und 13 weiteren Autor:innen. Beteiligte Einrichtung: Zoology and Entomology Department, Faculty of Science, Capital University, Helwan, Egypt. Hauptthemen laut MEDLINE: Neurodegenerative Diseases, Gastrointestinal Microbiome, Dysbiosis, Brain. Die Arbeit nennt 257 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
The microbiota–gut–brain axis (MGBA) is a bidirectional relationship between the gut microbiota (GM) and the brain, where the GM affects the gastrointestinal tract (GIT) and the central nervous system (CNS), and vice versa. Microbiotas are important for several vital body processes, including metabolism, immunity, and homeostasis. The MGBA has three main pathways: the vagal nerve mechanism, the immune‐related mechanism, and the neuroendocrine mechanism. GM imbalance, known as dysbiosis, affects the GIT, the brain, and the CNS. Furthermore, dysbiosis is linked to several neurological disorders such as Alzheimer's ( AD ), Parkinson's (PD), depression, autism spectrum disorder (ASD), and multiple sclerosis (MS). Studying MGBA gives researchers new therapeutic ideas using microbiota. Using special diets rich in fiber and probiotics, in addition to fecal microbiota transplantation (FMT), is being studied as a new therapy for MGBA. From the point of view that these therapeutic interventions maintain microbiota imbalance, which in turn will affect the brain and can relieve the neurological disorders caused by dysbiosis and MGBA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Zoology and Entomology Department, Faculty of Science, Capital University, Helwan, Egypt.
- Molecular Biology and Biotechnology Department, School of Biotechnology, Badr University in Cairo, Badr City, Cairo, Egypt.
- Pharmacology and Toxicology Department, Faculty of Pharmacy, Badr University in Cairo, Badr City, Cairo, Egypt.
- Department of Biology, College of Science, Imam Mohammad Ibn Saud Islamic University (IMSIU), Riyadh, Saudi Arabia.
- School of Biotechnology, Badr University in Cairo, Badr City, Cairo, Egypt.
- Department of Pharmacology, College of Medicine, University of Bisha, Bisha, Saudi Arabia.
ORCID-Profile: Reda M Mansour, Khaled M Alam-ElDein, Sherif S Abdel Mageed, Gharieb S El-Sayyad, Abanoub A S Shaker, Osama A Mohammed, Ahmed S Doghish
Zitieren
APA
Mansour, R. M., Alam-ElDein, K. M., Abdel Mageed, S. S., El-Sayyad, G. S., Ghanem, A., Shaker, A. A. S., Mohammed, O. A., Farag, D. A. A., Abdelnaby, M., Hathout, A., Adelaziz, R. Y., Ahmed, N. E., Mohamed, M. Y. A., & Doghish, A. S. (2026). Targeting the Microbiota–Gut–Brain Axis: Emerging Nanomedicine Approaches for Neurodegenerative Diseases. European Journal of Neuroscience, 64(2). https://doi.org/10.1111/ejn.70606
Vancouver
Mansour RM, Alam-ElDein KM, Abdel Mageed SS, El-Sayyad GS, Ghanem A, Shaker AAS, et al. Targeting the Microbiota–Gut–Brain Axis: Emerging Nanomedicine Approaches for Neurodegenerative Diseases. European Journal of Neuroscience. 2026;64(2). doi:10.1111/ejn.70606
BibTeX
@article{Mansour2026,
author = {Mansour, Reda M and Alam-ElDein, Khaled M and Abdel Mageed, Sherif S and El-Sayyad, Gharieb S and Ghanem, Aml and Shaker, Abanoub A S and Mohammed, Osama A and Farag, Dina Adel Attallah and Abdelnaby, Mariam and Hathout, Amira and Adelaziz, Rana Y and Ahmed, Nada E and Mohamed, Marwa Yousry A and Doghish, Ahmed S},
title = {Targeting the Microbiota–Gut–Brain Axis: Emerging Nanomedicine Approaches for Neurodegenerative Diseases},
journal = {European Journal of Neuroscience},
year = {2026},
volume = {64},
number = {2},
doi = {10.1111/ejn.70606}
}
EUVIMED